Global Market Research Group

"OpportunityAnalyzer: Pulmonary Arterial Hypertension - Opportunity Analysis and Forecasts to 2026" The Report covers current Industries Trends, Worldwide Analysis, Global Forecast, Review, Share, Size, Growth, Effect. . . Description- ' ' Pulmonary arterial hypertension (PAH) is a rare, fatal cardiopulmonary disease with an annual mortality rate of 15%. The disease is a subset (Group 1) within the World Health Organizations (WHOs) classification of the different types of pulmonary hypertension (PH). PAH is characterized by an abnormal rise in the resting mean pulmonary arterial pressure (>25mmHg compared with normal levels of around 14mmHg). This increased pressure is caused by pulmonary arterial obstruction due to endothelial dysfunction and vascular remodeling, and leads to increased resistance in the arterial blood vessels. Since PAH is a progressive disorder, the pulmonary pressure keeps building

"Global Pulmonary Arterial Hypertension (PAH) Market (By Drug Class, By Region, By Country): Opportunities and Forecasts (2016-2021) - (By Drug Class -Endothelin Receptor Antagonists, Prostacyclin & Prostacyclin Analogs, Phosphodiesterase V Inhibitors, Others; By Region-North America, Europe, APAC, Latin America, MEA; By Country- USA, Canada, UK, Germany, Japan, Brazil, South Africa)" The Report covers current Industries Trends, Worldwide Analysis, Global Forecast, Review, Share, Size, Growth, Effect. Description- A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of the global Pulmonary Arterial Hypertension (PAH) market on the basis of Drug Class (Endothelin Receptor Antagonists, Prostacyclin, Prostacyclin Analogs, Phosphodiesterase V Inhibitors, Others), By Region (North America, Europe, APAC, Latin America, MEA)

"Global Pulmonary Arterial Hypertension (PAH) Drugs Market 2017-2021" The Report covers current Industries Trends, Worldwide Analysis, Global Forecast, Review, Share, Size, Growth, Effect. Description- About Pulmonary Arterial Hypertension (PAH) Drugs PAH in the arteries, which carry blood from the heart to the lungs, occurs when blood vessels become narrow, making blood flow difficult. Technavios analysts forecast the global pulmonary arterial hypertension drugs market to grow at a CAGR of 3.2% during the period 2017-2021. Get Sample Report With TOC @ http://www.researchmoz.us/enquiry.php?type=S&repid=1063481 Covered in this report The report covers the present scenario and the growth prospects of the global pulmonary arterial hypertension drugs market for 2017-2021. To calculate the market size, the report considers the MoA and the RoA. The market is divided into the following segments based on geography: Americas APAC EMEA Technavio's r

"Pulmonary Arterial Hypertension - Pipeline Review, H2 2016" The Report covers current Market Trends, Analysis, Forecast, Review, Share, Size, Growth, Effect. Description- Global Markets Directs, Pulmonary Arterial Hypertension - Pipeline Review, H2 2016, provides an overview of the Pulmonary Arterial Hypertension pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pulmonary Arterial Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pulmonary Arterial Hypertension and features dormant and discontinued projects. Global Markets Directs repo